About: Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19
Creator	Sun, Yifei Sobieszczyk, Magdalena Schluger, Neil Baldwin, Matthew Geleris, Joshua Hripcsak, George Kubin, Christine Labella, Angelena Manson, Daniel Platt, Jonathan Zucker, Jason Graham Barr, R
Source	Medline; PMC
abstract	BACKGROUND: Hydroxychloroquine has been widely administered to patients with Covid-19 without robust evidence supporting its use. METHODS: We examined the association between hydroxychloroquine use and intubation or death at a large medical center in New York City. Data were obtained regarding consecutive patients hospitalized with Covid-19, excluding those who were intubated, died, or discharged within 24 hours after presentation to the emergency department (study baseline). The primary end point was a composite of intubation or death in a time-to-event analysis. We compared outcomes in patients who received hydroxychloroquine with those in patients who did not, using a multivariable Cox model with inverse probability weighting according to the propensity score. RESULTS: Of 1446 consecutive patients, 70 patients were intubated, died, or discharged within 24 hours after presentation and were excluded from the analysis. Of the remaining 1376 patients, during a median follow-up of 22.5 days, 811 (58.9%) received hydroxychloroquine (600 mg twice on day 1, then 400 mg daily for a median of 5 days); 45.8% of the patients were treated within 24 hours after presentation to the emergency department, and 85.9% within 48 hours. Hydroxychloroquine-treated patients were more severely ill at baseline than those who did not receive hydroxychloroquine (median ratio of partial pressure of arterial oxygen to the fraction of inspired oxygen, 223 vs. 360). Overall, 346 patients (25.1%) had a primary end-point event (180 patients were intubated, of whom 66 subsequently died, and 166 died without intubation). In the main analysis, there was no significant association between hydroxychloroquine use and intubation or death (hazard ratio, 1.04, 95% confidence interval, 0.82 to 1.32). Results were similar in multiple sensitivity analyses. CONCLUSIONS: In this observational study involving patients with Covid-19 who had been admitted to the hospital, hydroxychloroquine administration was not associated with either a greatly lowered or an increased risk of the composite end point of intubation or death. Randomized, controlled trials of hydroxychloroquine in patients with Covid-19 are needed. (Funded by the National Institutes of Health.)
has issue date	2020-05-07(xsd:dateTime)
bibo:doi	10.1056/nejmoa2012410
bibo:pmid	32379955
has license	no-cc
sha1sum (hex)	c000feb74cddc2ed8d9b4574713fa2df4623ad95
schema:url	https://doi.org/10.1056/nejmoa2012410
resource representing a document's title	Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19
has PubMed Central identifier	PMC7224609
has PubMed identifier	32379955
schema:publication	N Engl J Med
resource representing a document's body	covid:c000feb74cddc2ed8d9b4574713fa2df4623ad95#body_text
is schema:about of	named entity 'evidence' named entity 'Hydroxychloroquine' named entity 'Observational Study' named entity 'ethnic group' named entity 'Covid' named entity 'intubation' named entity 'hydroxychloroquine' named entity 'Wuhan' named entity 'end point' named entity 'assay' named entity 'pneumonia' named entity 'hydroxychloroquine' named entity 'hydroxychloroquine' named entity 'intubation' named entity 'clinical trial' named entity 'Data Extraction' named entity 'Food and Drug Administration' named entity 'respiratory illness' named entity 'safety profile' named entity 'hydroxychloroquine' named entity 'vital signs' named entity 'interquartile range' named entity 'hydroxychloroquine' named entity 'clinical guidelines' named entity 'asthma' named entity 'virus' named entity 'Columbia University Irving Medical Center' named entity 'loading dose' named entity 'inpatient and outpatient' named entity 'kidney disease' named entity 'd-dimer' named entity 'end point' named entity 'hazard ratio' named entity 'primary end-point' named entity 'hydroxychloroquine' named entity 'propensity scores' named entity 'missing data' named entity 'China' named entity 'hydroxychloroquine' named entity 'hydroxychloroquine' named entity 'hazard ratio' named entity 'control sample' named entity 'experimental group' named entity 'vital signs' named entity 'hydroxychloroquine' named entity 'ethnic group' named entity 'intubation' named entity 'laboratory tests' named entity 'chronic lung disease' named entity 'Cox regression' named entity 'regression model' named entity 'azithromycin' named entity 'randomized trial' named entity 'R Project' named entity 'hydroxychloroquine' named entity 'ethnic group' named entity 'hypertension' named entity 'human immunodeficiency virus' named entity 'viral burden' named entity 'Covid' named entity 'hydroxychloroquine' named entity 'intubation' named entity 'intubated' named entity 'Kaplan-Meier curves' named entity 'NEJM.org' named entity 'inverse probability weighting' named entity 'hydroxychloroquine' named entity 'Cox models' named entity 'hydroxychloroquine' named entity 'hazard ratio'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software